Biomx End Period Cash Flow Over Time
PHGE Stock | USD 0.55 0.01 1.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biomx Performance and Biomx Correlation. Biomx |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomx. If investors know Biomx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.26) | Return On Assets (0.33) | Return On Equity (1.21) |
The market value of Biomx Inc is measured differently than its book value, which is the value of Biomx that is recorded on the company's balance sheet. Investors also form their own opinion of Biomx's value that differs from its market value or its book value, called intrinsic value, which is Biomx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomx's market value can be influenced by many factors that don't directly affect Biomx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities End Period Cash Flow Analysis
Compare Biomx Inc and related stocks such as Kiromic Biopharma, ZyVersa Therapeutics, and YS Biopharma Co, End Period Cash Flow Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ZVSA | 174.7 K | 174.7 K | 174.7 K | 174.7 K | 174.7 K | 174.7 K | 174.7 K | 174.7 K | 174.7 K | 174.7 K | 174.7 K | 328.6 K | 699.3 K | 3.1 M | 3.3 M |
IMMX | 734 K | 734 K | 734 K | 734 K | 734 K | 734 K | 734 K | 734 K | 734 K | 734 K | 391.1 K | 17.6 M | 13.4 M | 17.5 M | 10.9 M |
CNSP | 110.5 K | 110.5 K | 110.5 K | 110.5 K | 110.5 K | 110.5 K | 110.5 K | 110.5 K | 555.1 K | 7.2 M | 14 M | 5 M | 10.1 M | 548.7 K | 521.3 K |
SONN | 165.1 K | 165.1 K | 442.7 K | 245.8 K | 245.8 K | 1.5 M | 438.5 K | 273 K | 524.1 K | 35.7 K | 27.6 M | 3.1 M | 2.3 M | 35.7 K | 33.9 K |
Biomx Inc and related stocks such as Kiromic Biopharma, ZyVersa Therapeutics, and YS Biopharma Co, End Period Cash Flow description
My Equities
My Current Equities and Potential Positions
Biomx Inc | PHGE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Location | New York; U.S.A |
Exchange | NYSE MKT Exchange |
USD 0.55
Check out Biomx Performance and Biomx Correlation. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Biomx technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.